Estland - estisk - Ravimiamet

piramal critical care b.v. - sevofluraan - inhalatsiooniaur, vedelik - 100% 250ml 6tk; 100% 250ml 1tk

Den europeiske union - estisk - EMA (European Medicines Agency)

proveca pharma limited - enalapril (maleate) - südamepuudulikkus - reniini-angiotensiini süsteemi toimivad ained - treatment of heart failure.

Den europeiske union - estisk - EMA (European Medicines Agency)

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - immunosupressandid - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

Estland - estisk - Ravimiamet

sun pharmaceutical industries europe b.v. - meropeneem - süste-/infusioonilahuse pulber - 1g 10tk; 1g 1tk

Estland - estisk - Ravimiamet

sun pharmaceutical industries europe b.v. - meropeneem - süste-/infusioonilahuse pulber - 500mg 10tk

Estland - estisk - Ravimiamet

casen recordati s.l. - makrogool - suukaudse lahuse pulber kotikeses - 4g 4g 50tk; 4g 4g 10tk; 4g 4g 30tk

Den europeiske union - estisk - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuuria, paroksüsmaalne - selektiivsed immunosupressandid - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Estland - estisk - Ravimiamet

abbvie limited - isofluraan - inhalatsiooniaur, vedelik - 100ml 1tk; 250ml 1tk

Den europeiske union - estisk - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunosupressandid - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Estland - estisk - Ravimiamet

abbvie sia - sevofluraan - inhalatsiooniaur, vedelik - 100ml 1tk; 250ml 1tk